Here are four points:
1. Dr. Bright will be responsible for strategic business and corporate development activities as well as potential partnering opportunities for the company’s drug candidates.
2. Most recently, Dr. Bright led the U.S. private equity investment practice as a partner at Merieux Development.
3. He also previously served as vice president, corporate development and diagnostics for QuantaLife.
4. Synthetic Biologics’s drug candidates include SYN-010, designed to reduce methane production in the gut to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004, designed to prevent C. difficile infection, antibiotic associated diarrhea and the emergence of antibiotic resistant organisms.
More articles on GI/endoscopy:
MACRA proposed rule release: 4 ways it will affect gastroenterologists
Fuse system delivers higher ADR rate than traditional colonoscopies: 3 findings
FDA stops requesting a Custom Ultrasonics endoscope repreocessor recall: 7 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.